Prof. Bo Xu serves as Vice President of Tianjin Medical University Cancer Institute and Hospital (TMUCIH) and the Executive Director of Tianjin Breast Cancer Center. He is also the President of Society of Artificial intelligence in Oncology for China Anti-Cancer Association. Before joining TMUCIH, he had been Chairman of Oncology Department at Southern Research Institute (SRI) and Professor of Pathology at University of Alabama at Birmingham (UAB), where he headed the long-standing cancer research program at SRI. Dr. Xu received Ph.D. degree (1998) in Radiation Oncologyfrom the Peking Union Medical College and he completed his postdoctoral training at St. Jude Children’s Research Hospital in Memphis, TN. In 2002, Dr. Xu started his independent research at the LSU Health Sciences Center in New Orleans as Assistant Professor in the Department of Genetics. He joined SRI in 2006, serving as Head of the Molecular Radiobiology Laboratory. Between 2009-2012, he had served as Professor and Director of Molecular Radiation Oncology Laboratory in The Methodist Hospital, Weill Cornell Medical College of Cornell University.Dr. Xu’s major research interest is on molecular mechanisms of the DNA damage response. He has published more than 75 peer-review papers in major biomedical journals (including Nature, Cell, Molecular Cell), with more than 7500 citations. Six of his papers have been recommended by Faculty 1000.
